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Abstract
Background: Infection with varicella-zoster virus (VZV) contemporaneously with malignant disease or
immunosuppression represents a particular challenge and requires individualized decisions and treatment.
Although the increasing use of varicella-vaccines in the general population and rapid initiation of VZV-
immunoglobulins and acyclovir in case of exposure has been beneficial for some patients, immunocompromised
individuals are still at risk for unfavourable courses.
Methods: In this single center, 6-year analysis we review incidence, hospitalization and complication rates of VZV-
infections in our center and compare them to published data. Furthermore, we report three instructive cases.
Results: Hospitalization rate of referred children with VZV-infections was 45%, among these 17% with malignancies
and 9% under immunosuppressive therapy. Rate of complications was not elevated in these two high-risk cohorts,
but one ALL-patient died due to VZV-related complications. We report one 4-year old boy with initial diagnosis of
acute lymphoblastic leukemia who showed a rapidly fatal outcome of his simultaneous varicella-infection, one 1.8-
year old boy with an identical situation but a mild course of his disease, and an 8.5-year old boy with a steroid-
dependent nephrotic syndrome. This boy developed severe hepatic involvement during his varicella-infection but
responded to immediate withdrawl of steroids and administration of acyclovir plus single-dose cidofovir after
nonresponse to acyclovir after 48 h.
Conclusion: Our data show that patients with malignant diseases or immunosuppressive therapy should be
hospitalized and treated immediately with antiviral agents. Despite these measures the course of VZV-infections
can be highly variable in these patients. We discuss aids to individual decision-making for these difficult situations.
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Background
Infections with varicella-zoster virus (VZV) are usually
considered benign infections. However, severe complica-
tions including bacterial superinfections, coagulopathies,
and central nervous system manifestations with a poten-
tially fatal or long term disabling outcome can occur
[1,2]. The classical clinical presentation is characterized
by mucocutaneous involvement and a low mortality rate
in immunocompetent children. In contrast, primary var-
icella-infections are potentially life-threatening in immu-
nocompromised patients, especially in those whose
immune system has been suppressed by diseases such as
acute lymphoblastic leukaemia (ALL) or by multiagent
chemotherapy treatment including corticosteroids.
After introduction of antiviral treatment with acyclovir
and varicella-zoster immune globulin (VZIG), mortality
rate of varicella-infections in children with immune sup-
pression has decreased significantly (<1%). Before intro-
duction of antiviral therapy, the mortality rate of
varicella infections in children with cancer was reported
to be 7%, with numbers reaching up to 55% in cases
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with visceral involvement [3-6]. In immunocompro-
mised patients the diagnosis of varicella may be
obscured by atypical or even absent skin lesions in com-
bination with systemic viral disease [5,7,8].
The management of VZV-infection in immunocompro-
mised patients can represent a challenging dilemma for
the treating physician due to the balance between infection
and underlying disease. The limited published evidence to
support specific therapeutic management processes
prompted us to report our recent experience in clinical
decision making in patients with overt VZV-infections
under immunosuppression and/or malignancies.
Methods
All patients with VZV-infections treated in the emer-
gency room of the University Children’s Hospital Würz-
burg between January 2004 and March 2010 were
identified using ICD-10 hospital discharge diagnosis sys-
tem and their medical charts were reviewed for hospita-
lization, treatment, treatment duration, occurrence of
complications, and outcome. The identified patient
cohort was further divided into subgroups with either a
underlying malignancy, disorders requiring immunosup-
pressive therapy or none of these two conditions.
Through this we could calculate local hospitalization,
treatment, and complication rates of VZV infections.
Furthermore, rate and severity of VZV-related complica-
tions were compared between healthy and immunosup-
pressed children. Acquired data were compared with a
review of the literature. Keywords for literature search
were varicella zoster virus infection, immunosuppres-
sion, malignancy and complications. Finally, three
instructive cases of children with VZV-infections and
high-risk conditions are reported in detail.
Patients and/or guardians treated in our academic
hospital gave informed consent to scientific analysis and
anonymized publication of their medical data in accor-
dance with the Declaration of Helsinki. The ethical
committee of the University Hospital Würzburg has
determined that for analysis and publication of single
center case series this informed consent is sufficient and
no specific review of retrospective data analysis projects
are required.
Results
A total of 119 children with VZV-infections have been
seen at the emergency room of the University Children’s
Hospital Würzburg between January 01, 2004 and March
31, 2010. The median age of these 119 children was 3.8
years (range: four weeks to 18 years). 54 out of these 119
patients (45%) were hospitalized. Out of the 54 admitted
children 40 (74%) did not have a severe underlying dis-
ease, 9 patients (16.7%) had an oncologic disorder and 5
patients (9.3%) received an immunosuppressive
treatment. VZV-infection and/or risk factors for a com-
plicated course were the prime indication for in-patient
care in all cases. None of the patients with malignancies
or immunosuppression were treated on an outpatient
basis and all received intravenous acyclovir as antiviral
treatment immediately. From the 40 patients without a
severe underlying disease 6 (15%) developed complica-
tions of their VZV-infection (5 cerebellitis, 1 coagulopa-
thy). In each of the high-risk groups one patient
developed a complicated course (Table 1), resulting in a
complication rate of 11% versus 20% (malignant disease
vs. immunosuppression, respectively).
Among the 9 children with underlying oncologic dis-
eases 7 were diagnosed with acute lymphoblastic leukae-
mia (ALL), 1 with neuroblastoma and 1 with an
astrocytoma of the CNS. Children with immunosuppres-
sive therapy were treated due to nephrotic syndrome (n
= 1, patient 10), pemphygoid and enteropathy (n = 1)
and rheumatic disease (n = 2). We recorded one VZV-
related death in a child with ALL (patient 1).
Case presentations
Patient 1
A 4 year old boy presented with a two day history of
macro-hematuria, fatigue, and emesis as well as a one
day history of varicella-like skin lesions. An exposure to
varicella three to four weeks ago had been reported.
Occurrence of blue spots (hematoma) had been noted
on his lower legs in the last few days before admission.
There was no history of epistaxis or other signs of
bleeding, respectively.
Immediate blood and bone marrow diagnostic tests
confirmed the initial suspicion of the simultaneous clini-
cal manifestation of acute varicella-infection and acute
lymphoblastic leukaemia. Leukocytosis (leukocytes
69,810/μl) accompanied with mild anemia (Hb 11.5 g/
dl) and thrombocytopenia (62,000/μl), an enlargement
of the thymus in conventional chest X-ray (Figure 1A)
and 80% blast cells in bone marrow revealed an acute
lymphoblastic leukaemia (Figure 1D), which exhibited a
T-precursor phenotype in subsequent flow cytometric
assessment. Varicella-infection was proven by VZV-
DNA detection in vesicles and blood, while both VZV-
IgM and -IgG were negative at admission (48 hours
after the first appearance of skin lesions).
The patient was clinically in a stable cardiopulmonary
condition, so we refrained from starting antileukemic
therapy with corticosteroids to allow for viral control.
Instead, immediate treatment with intravenous acyclovir
(45 mg/kg BW/d) and specific immunoglobulin (Varitect
100 mg/kg BW) was initiated.
In the first few hours thereafter the patient remained
in stable clinical condition. Due to leukocytosis and the
inherent risk of tumor-lysis-syndrome he received
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hydration plus diuretic therapy, resulting in an even
fluid balance. Even without receiving corticosteroids a
progressive reduction of leukocyte counts from 70,000/
μl initially to 9,000/μl was observed, in addition the thy-
mus decreased in size.
Four hours after initiation of treatment, a minor oxy-
gen demand could be noted, the current chest x-ray
showed increasing pulmonary infiltrates (Figure 1B).
Otherwise, the clinical condition remained stable, the
patient was able to eat and play.
During the next few hours the previously stable clini-
cal condition worsened dramatically with increasing
oxygen demand, but despite maximal oxygen supply the
patient showed signs of respiratory distress with a
venous oxygen saturation of below 90%.
Subsequently, the patient was transferred to the inten-
sive care unit (ICU), where mechanical ventilation
became necessary. The patient subsequently developed a
severe hemorrhagic pulmonary edema as evidenced by
bloody-foamy tracheal secretion (Figure 1C). At this
Table 1 Patient characteristics
patient gender age
[years]
start VZV
exanthema
until hospital
admission
organ involvement start antiviral
therapy
underlying
disease/time
point of therapy
duration of
antiviral
therapy
outcome
Oncologic patients
1 m 4 1 day skin, peripheral blood, bronchial
secret, pleural effusion, ascites,
myocard, lung, liver, kidneys
immediately,
acyclovir i.v.
T-ALL, diagnosis until death
(2nd Day)
death of
VZV
2 m 6 same day skin immediately,
acyclovir i.v.
c-ALL, maintenance
therapy
7 days alive, no
sequelae
3 m 4 same day skin immediately,
acyclovir i.v.
neuroblastoma,
maintenance with
retinoic acid
7 days alive, no
sequelae
4 m 5 same day skin immediately,
acyclovir
T-ALL,
consolidation
chemotherapy,
herpes zoster
7 days alive, no
sequelae
5 m 8 same day skin immediately,
acyclovir i.v.
T-ALL, induction
chemotherapy
5 days alive, no
sequelae
6 f 1 same day skin immediately,
acyclovir i.v.
astrocytoma,
induction therapy
7 days alive, no
sequelae
7 m 7 same day skin immediately,
acyclovir i.v.
pro-B-ALL,
allogeneic BMT, d
+114, herpes zoster
7 days DOD
8 m 7 same day skin immediately,
acyclovir i.v.
pro-B-ALL,
allogeneic BMT, d
+60, herpes zoster
7 days DOD
9 m 1.8 3 days later skin immediately,
acyclovir i.v.
cALL, diagnosis 49 days alive, no
sequelae
Immunocompromised patients
10 m 8 1 day skin, liver immediately,
acyclovir and
cidofovir
nephrotic
syndrome
7 days alive, no
sequelae
11 f 7 1 day skin immediately,
acyclovir i.v.
juvenile idiopathic
arthritis (MTX,
prednisone)
3 days i.v., 5
days p.o.
alive, no
sequelae
12 f 5 same day skin immediately,
acyclovir i.v.
juvenile idiopathic
arthritis (MTX,
prednisone)
3 days* alive, no
sequelae
13 f 4
weeks
3 days skin immediately,
acyclovir i.v.
neonatal 4 days alive, no
sequelae
14 m 3 same day skin immediately,
acyclovir i.v.
pemphygoid,
enteropathy
(prednisone)
14 days alive, no
sequelae
All patients were admitted due to VZV-infections and/or the presence of risk factors for a complicated course of the disease.
*Antiviral therapy was stopped after only three days due to acute, but transient renal failure under acyclovir.
Abbreviations: BMT = bone marrow transplantation, c-ALL = common acute lymphoblastic leukemia, d = day, i.v.= intravenously, MTX = methotrexate, DOD =
dead of underlying oncologic disease, p.o.= orally, pro-B-ALL = B-progenitor acute lymphoblastic leukemia, VZV = varicella zoster virus
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time point the patient showed centralisation, dissemi-
nated intravascular coagulation, and fulminant multi-
organ failure to which he succumbed only three hours
after the admission to the ICU.
Post mortem autopsy report showed an enlargement
and consolidation of thymus, spleen, and lymph nodes,
pulmonary edema with subpleural echymosis. Further-
more, a dilatation of the right ventricle, leukostasis in
the lungs (Figure 1E), liver (Figure 1F) and spleen,
shock-kidneys, signs of disseminated intravascular coa-
gulopathy in several organs together with peritoneal,
pericardial and pleural effusions could be observed.
VZV-DNA could be detected in peripheral blood, bron-
chial lavage, pleural effusion, ascites, myocard, lung,
liver and kidneys. Pericardial effusion was negative for
VZV.
Endogenous cortisol production was measured retro-
spectively in backup serum samples. There was a clear
increase in endogenous cortisol production from 396
ng/ml at admission to values beyond the detection limit
(>500 ng/ml) during the course on the ICU [age adapted
normal values 2.5-230 ng/ml at 8 a.m.].
Patient 9
A 20 month old boy was admitted to our hospital with
signs of anemia and thrombocytopenia. Subsequent eva-
luation revealed acute lymphobastic leukemia of preB-
precursor phenotype (cALL). Leukocytes in peripheral
blood were 14,880/μl (76% blasts), Hb 6.1 g/dl, throm-
bocytes 8,000/μl, and 95% blast cells in bone marrow.
Careful evaluation of medical history revealed that the
patient’s sister has been diagnosed with chickenpox two
weeks ago. The patient had received a single dose of
varicella-vaccination 7 months earlier, but was negative
for VZV-IgG and -IgM at presentation. Due to the
stable condition of the patient and this significant risk
factor we postponed antileukemic therapy with steroids
and only initiated antiviral treatment (acyclovir 45 mg/
kg BW/d), hydration and close clinical surveillance of
the patient. In fact, 3 days after admission the boy devel-
oped skin lesions (approximately 20-30 lesions) compati-
ble with primary varicella-infection. However, these
lesions were described as “atypical varicella” by a con-
sulting dermatologist due to the reduced inflammatory
halo around the vesicles. The content of the vesicles
proved to be positive for VZV-DNA, while repeated
PCR-testing in blood did not give positive results. Under
continuous hydration, antiviral therapy with acyclovir
and a wait-and-see strategy the lesions slowly disap-
peared without further complications within two weeks.
A DNA-swab from a vesicle 10 days after the appear-
ance of the first one was negative for VZV. Three days
later (16 days after admission to the hospital) therapy
with corticosteroids as the first part of ALL-induction
Figure 1 Serial chest X-rays displaying the fulminant course of disease. Upon admission a mediastinal tumour was described (A). 23 hours
after admission, the mediastinal tumour diminished, however, bilateral pulmonary infiltrates could be noted (B) which progressed rapidly (C, 6
hours later). D) bone marrow aspiration at diagnosis: 80% T-lymphatic blasts, E) histology of lung parenchyma: pulmonary capillaries obstructed
by lymphatic blasts, no interstitial infiltrations of the lung parenchyma, pulmonary edema due to leukostasis (autopsy tissue), F) Histology of liver:
liver cells with inflammatory signs (autopsy tissue).
Wiegering et al. BMC Pediatrics 2011, 11:31
http://www.biomedcentral.com/1471-2431/11/31
Page 4 of 7
therapy was initiated. The boy showed a fast and sus-
tained prednisone-response of his ALL and did not reac-
tivate VZV during subsequent chemotherapy. Acyclovir
medication was continued until the end of the induction
protocol. The patient did not developed anti-VZV anti-
bodies during ALL treatment.
Patient 10
A 8.5 year old boy with a chronic nephrotic syndrome
presented with typical varicella skin lesions on his trunk
and pilous head, leg pain, and fatigue. Varicella-infection
could be confirmed by VZV-DNA detection in vesicles,
while both VZV-IgM and -IgG were still negative at this
early time point of infection. Due to his underlying dis-
ease the patient had received prednisolone 60 mg/m2
for the last month. Therefore an immediate intravenous
therapy with acyclovir (30 mg/kg BW/d) was started;
prednisolone was discontinued. Despite these measures
the patient’s clinical condition worsened with decreasing
liver function tests (maximum of laboratory findings on
the third day after admission [age adapted reference
range]: GOT: 1012 U/l [12-51], GPT: 1409 U/l [7-44],
GGT: 29.3 U/l [5-25], LDH: 2697 U/l [88-298], Albumin
2.8 g/dl [3.5-5.5] and Cholinesterase: 4000 U/L [5500-
13000], see Figure 2) and signs of disseminated intravas-
cular coagulation (D-dimers 20.98 mg/l [normal range
0-0.5]). However, vital parameters remained stable dur-
ing the hospital stay. Because of the rapid clinical
deterioration under acyclovir therapy we decided to
administer a single dose of cidofovir (5 mg/kg) as an
experimental therapy due to the critical illness of the
patient after obtaining informed parental consent. The
decision for cidofovir was based on the conception that
a second antiviral drug with a different mode of action
(acyclic nucleoside phosphonate without the need for
activation by the viral thymidine kinase) [9] and a pro-
ven effect on many herpesviridae [10] could favorably
influence the course of the disease. In the following
days, clinical condition and laboratory findings improved
and the boy could be discharged nine days later. No
renal side-effects of cidofovir treatment could be
observed.
Discussion
Immunocompromised patients are threatened by severe
infections, in part by infectious agents which rarely cause
complications in non-immunosuppressed children. VZV-
infections in this patient cohort have an increased risk of
serious morbidity and even death [1]. Before the era of
antiviral therapy, disseminated and/or fatal VZV infec-
tions have been described in children with cancer under
chemotherapy, especially in acute lymphoblastic leukemia
[3]. Recently, an increasing general awareness of vari-
cella-related complications has led to the assumption
that hospitalization with subsequent severe complications
occurs in approximately 20% of VZV-infected, immuno-
compromised patients [1]. Most frequently described
complications of VZV-infection during chemotherapy
and immunosuppression are interstitial or necrotising
pneumonia, viral hepatitis with acute liver failure, coagu-
lopathies or bacterial superinfections [8,11]. In contrast,
VZV-infected immunocompetent children were reported
to have a higher incidence of neurologic complications
(32% vs. 15%, immunocompetent vs. immunosuppressed
children, respectively) or cutaneous bacterial superinfec-
tions (30% vs. 7%) [1,2]. Interestingly, infections mani-
festing as herpes zoster in these immunocompromised
patients were not associated with more complications
with exception of a generalised zoster rash, which has
been reported to occur in 25% [12]. Our three patients
with herpes zoster manifestations (patient 4, 7, and 8) did
not develop any complications.
Out of 119 patients seen with VZV infections we could
identify 14 immunocompromised/oncologic patients in
six years (11.8%). All were immediately hospitalized for
therapeutic antiviral treatment. With the exception of
one case (patient 1), early and consequent antiviral treat-
ment was effective in preventing severe courses so that
the overall complication rate in the two high-risk groups
was not elevated compared to the otherwise healthy
group. This is in contrast to other reports in the litera-
ture, which show a higher risk of complications and
Figure 2 Timely relationship between laboratory values (LDH =
lactate dehydrogenase and ALAT = alanine aminotransferase)
and therapeutic measures in patient 10. 48 h after
discontinuation of steroid treatment and initiation of antiviral
treatment with acyclovir, liver enzymes continued to increase
whereas liver function parameters declined (not shown). Addition of
cidofovir (single dose) to acyclovir was followed by a rapid and
sustained normalization of liver function parameters.
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death in leukemic children with VZV infections [1,3].
However, the only death occurred in a child with ALL, a
disease that was overrepresented compared to other
malignancies (7 patients with ALL vs. 1 case with neuro-
blastoma and 1 case with an astrocytoma).
Several reports describe liver failure without other
organ manifestations due to VZV in immunocompro-
mised patients [5,7,8,13], which seems to be a typical
clinical manifestation in oncology patients. Rapid dete-
rioration of liver function in patient 10 under acyclovir
therapy suggested such a course with a presumed non-
response to this drug. Thus, we expanded antiviral ther-
apy by the application of a single dose of cidofovir. This
decision was based on the relatively beneficial toxicity
profile of cidofovir after short term application [14], in-
vitro data showing antiviral activity against acyclovir-
and foscarnet-resistant VZV-strains [9], experience with
the efficiency of cidofovir in herpesviridae infections in
oncology patients [10], and the long half-life after a sin-
gle dose. One day after the application of cidofovir, liver
parameters improved and returned to normal within
one week. However, it remains unclear, whether this
success is attributable to cidofovir or rather to the
improving immune function after cessation of steroids
two days earlier. Anecdotal reports exist which demon-
strate good responses of acyclovir-resistant VZV-strains
to alternative substances such as forscarnet or cidofovir
[12,15]. However, an acyclovir-resistant strain can hardly
be claimed in this situation, as these are mainly isolated
from immunocompromised patients after long-term acy-
clovir administration. The efficacy of alternative viral
drugs such as foscarnet or cidofovir alone or in combi-
nation with standard antiviral substances especially in
high-risk situations certainly warrants further investiga-
tion in larger, controlled trials.
Our two cases of VZV-infections in children with
newly diagnosed ALL exhibited highly divergent courses.
Whereas in patient 9, ALL therapy could be postponed
safely until viral control was obtained, patient 1 took a
fulminant fatal course within hours after admission
despite all therapeutic interventions. Although we could
not detect protective anti-VZV-titers, it can be discussed
whether patient 9 may have benefitted from the pre-
vious single varicella-vaccination seven months earlier.
The autopsy report in patient 1 described pulmonary
leukostasis as the most likely explanation for the fatal
respiratory failure and right ventricle dilatation. Several
adhesion molecules were upregulated on pulmonary
endothelial cells (data not shown). We hypothesize that
in this case pulmonary VZV-infection triggered a prefer-
ential clustering of T-ALL blasts in pulmonary capil-
laries via an increased expression of adhesion molecules.
Interestingly, whereas VZV-DNA could be found in
nearly every organ, blast cells could only be found in
terminal capillary vessels. This phenomenon has already
been described for myeloid blasts [16]. Together with
the increased endogenous cortisol production, this pre-
ferential sequestration of blasts into the pulmonary cir-
culation provides an explanation for both the rapidly
diminishing leukocyte counts and for the progressive
right heart and respiratory failure. It remains speculative
whether an initiation of steroid treatment despite sys-
temic VZV-infection could have prevented obstruction
of pulmonary circulation system.
Routine vaccination against varicella, as recently estab-
lished in Germany, has a great potential to significantly
reduce the burden of this disease, if sufficiently high
coverage is reached in the target population. Vaccination
can not only reduce the number of infections and infec-
tion-related complications but also provide herd immu-
nity. Especially immunocompromised children may
profit from this. In Germany it could already be demon-
strated, that complications and mortality of varicella
infections significantly decreased since the introduction
of varicella-vaccines in the standard childhood vaccina-
tion schedule [17].
Conclusions
Our retrospective, 6-year single centre data show that
immunocompromised children with VZV-infections are
frequently hospitalized and rapidly receive antiviral ther-
apy. Using this approach even in this high-risk patient
cohort severe VZV-related complications are rare, how-
ever, they cannot be prevented in all cases, especially in
newly diagnosed immunocompromised children. Para-
meters that may predict an adverse clinical outcome can
be duration and intensity of immunosuppression, biolo-
gical course and phenotype of leukemia (T-versus pre-
cursor B-cell-phenotype), time post transplantation/
chemotherapy and degree of immune reconstitution
achieved so far. Close monitoring of organ function and
viral load can identify patients not responding to acyclo-
vir who may then be considered candidates for alterna-
tive therapies such as foscarnet or cidofovir. However,
this approach should be evaluated in larger patient ser-
ies. Additional experimental data will have to show, if a
relationship between T-phenotype ALL, systemic inflam-
mation and a preferential homing of blasts into the pul-
monary circulation system can be established.
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